Agile Therapeutics (NASDAQ:AGRX) Trading Down 7.9%

Agile Therapeutics Inc (NASDAQ:AGRX)’s stock price fell 7.9% during mid-day trading on Friday . The stock traded as low as $1.23 and last traded at $1.29, 500,635 shares were traded during trading. An increase of 35% from the average session volume of 371,070 shares. The stock had previously closed at $1.40.

Several research firms have recently issued reports on AGRX. Maxim Group set a $3.00 price objective on Agile Therapeutics and gave the stock a “buy” rating in a research report on Monday, June 10th. Janney Montgomery Scott began coverage on PLx Pharma in a research report on Friday, April 12th. They set a “buy” rating for the company. ValuEngine cut Wolverine World Wide from a “hold” rating to a “sell” rating in a research report on Monday, May 20th. Finally, Oppenheimer began coverage on Southwestern Energy in a research report on Thursday, June 6th. They set a “market perform” rating for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Agile Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $4.00.

The company has a 50-day moving average price of $1.36. The firm has a market capitalization of $61.24 million, a price-to-earnings ratio of -2.22 and a beta of 0.65. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.01.

Agile Therapeutics (NASDAQ:AGRX) last posted its earnings results on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.02). On average, equities analysts forecast that Agile Therapeutics Inc will post -0.44 earnings per share for the current year.

In other news, CEO Alfred Altomari bought 20,000 shares of Agile Therapeutics stock in a transaction dated Monday, June 10th. The stock was acquired at an average cost of $1.27 per share, with a total value of $25,400.00. Following the acquisition, the chief executive officer now owns 258,568 shares of the company’s stock, valued at $328,381.36. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 8.50% of the stock is currently owned by insiders.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. lifted its holdings in shares of Agile Therapeutics by 15.7% in the 4th quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock valued at $77,000 after purchasing an additional 18,038 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Agile Therapeutics by 24.0% in the 4th quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock valued at $132,000 after purchasing an additional 44,639 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in shares of Agile Therapeutics by 33.3% in the 1st quarter. Acadian Asset Management LLC now owns 417,269 shares of the specialty pharmaceutical company’s stock valued at $630,000 after purchasing an additional 104,222 shares during the last quarter. 42.38% of the stock is owned by institutional investors and hedge funds.

Agile Therapeutics Company Profile (NASDAQ:AGRX)

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Featured Story: Cash Flow

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.